Breaking barriers to novel analgesic drug development

被引：231

作者：

Yekkirala, Ajay S. ^{[1
,2
,3
]}

Roberson, David P. ^{[1
,2
,3
]}

Bean, Bruce P. ^{[1
]}

Woolf, Clifford J. ^{[1
,2
]}

机构：

[1] Harvard Med Sch, Boston Childrens Hosp, Dept Neurobiol, 300 Longwood Ave, Boston, MA 02115 USA

[2] Boston Childrens Hosp, FM Kirby Neurobiol Ctr, 300 Longwood Ave, Boston, MA 02115 USA

[3] Blue Therapeut, Harvard Innovat Launch Lab, 114 Western Ave, Allston, MA 02134 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2017年 / 16卷 / 08期

基金：

美国国家卫生研究院;

关键词：

MU-OPIOID RECEPTOR; CALCIUM-CHANNEL BLOCKER; II TYPE-2 RECEPTOR; ROOT GANGLION NEURONS; MECHANICAL PAIN HYPERSENSITIVITY; PERIPHERAL NERVOUS-SYSTEM; PLACEBO-CONTROLLED TRIAL; CHRONIC CANCER PAIN; NEUROPATHIC PAIN; POTASSIUM CHANNELS;

D O I：

10.1038/nrd.2017.87

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Acute and chronic pain complaints, although common, are generally poorly served by existing therapies. This unmet clinical need reflects a failure to develop novel classes of analgesics with superior efficacy, diminished adverse effects and a lower abuse liability than those currently available. Reasons for this include the heterogeneity of clinical pain conditions, the complexity and diversity of underlying pathophysiological mechanisms, and the unreliability of some preclinical pain models. However, recent advances in our understanding of the neurobiology of pain are beginning to offer opportunities for developing novel therapeutic strategies and revisiting existing targets, including modulating ion channels, enzymes and G-protein-coupled receptors.

引用

页码：544 / 563

页数：20

共 285 条

[1] Analgesic Effects of a Substituted N-Triazole Oxindole (TROX-1), a State-Dependent, Voltage-Gated Calcium Channel 2 Blocker [J].

Abbadie, Catherine ;

McManus, Owen B. ;

Sun, Shu-Yu ;

Bugianesi, Randal M. ;

Dai, Ge ;

Haedo, Rodolfo J. ;

Herrington, James B. ;

Kaczorowski, Gregory J. ;

Smith, McHardy M. ;

Swensen, Andrew M. ;

Warren, Vivien A. ;

Williams, Brande ;

Arneric, Stephen P. ;

Eduljee, Cyrus ;

Snutch, Terrance P. ;

Tringham, Elizabeth W. ;

Jochnowitz, Nina ;

Liang, Annie ;

MacIntyre, D. Euan ;

McGowan, Erin ;

Mistry, Shruti ;

White, Valerie V. ;

Hoyt, Scott B. ;

London, Clare ;

Lyons, Kathryn A. ;

Bunting, Patricia B. ;

Volksdorf, Sylvia ;

Duffy, Joseph L. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 334 (02) :545-555

[2] Chemokines and pain mechanisms [J].

Abbadie, Catherine ;

Bhangoo, Sonia ;

De Koninck, Yves ;

Malcangio, Marzia ;

Melik-Parsadaniantz, Stephane ;

White, Fletcher A. .

BRAIN RESEARCH REVIEWS, 2009, 60 (01) :125-134

[3] MDAN-21: A Bivalent Opioid Ligand Containing mu-Agonist and Delta-Antagonist Pharmacophores and Its Effects in Rhesus Monkeys [J].

Aceto, Mario D. ;

Harris, Louis S. ;

Negus, S. Stevens ;

Banks, Matthew L. ;

Hughes, Larry D. ;

Akgun, Eyup ;

Portoghese, Philip S. .

INTERNATIONAL JOURNAL OF MEDICINAL CHEMISTRY, 2012, 2012

[4] Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5) [J].

Akguen, Eyup ;

Javed, Muhammad I. ;

Lunzer, Mary M. ;

Powers, Michael D. ;

Sham, Yuk Y. ;

Watanabe, Yoshikazu ;

Portoghese, Philip S. .

JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (21) :8647-8657

[5]

Akgun Eyup, 2013, Proc Natl Acad Sci U S A, V110, P11595, DOI 10.1073/pnas.1305461110

[6] Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists [J].

Altun, Ahmet ;

Yildirim, Kemal ;

Ozdemir, Ercan ;

Bagcivan, Ihsan ;

Gursoy, Sinan ;

Durmus, Nedim .

JOURNAL OF PHYSIOLOGICAL SCIENCES, 2015, 65 (05) :407-415

[7] Angiotensin II type 2 receptor (AT2R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons [J].

Anand, U. ;

Facer, P. ;

Yiangou, Y. ;

Sinisi, M. ;

Fox, M. ;

McCarthy, T. ;

Bountra, C. ;

Korchev, Y. E. ;

Anand, P. .

EUROPEAN JOURNAL OF PAIN, 2013, 17 (07) :1012-1026

[8] Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies [J].

Anand, Uma ;

Yiangou, Yiangos ;

Sinisi, Marco ;

Fox, Michael ;

MacQuillan, Anthony ;

Quick, Tom ;

Korchev, Yuri E. ;

Bountra, Chas ;

McCarthy, Tom ;

Anand, Praveen .

MOLECULAR PAIN, 2015, 11

[9] Ensuring transparency and minimization of methodologic bias in preclinical pain research: PPRECISE considerations [J].

Andrews, Nick A. ;

Latremoliere, Alban ;

Basbaum, Allan I. ;

Mogil, Jeffrey S. ;

Porreca, Frank ;

Rice, Andrew S. C. ;

Woolf, Clifford J. ;

Currie, Gillian L. ;

Dworkin, Robert H. ;

Eisenach, James C. ;

Evans, Scott ;

Gewandter, Jennifer S. ;

Gover, Tony D. ;

Handwerker, Hermann ;

Huang, Wenlong ;

Iyengar, Smriti ;

Jensen, Mark P. ;

Kennedy, Jeffrey D. ;

Lee, Nancy ;

Levine, Jon ;

Lidster, Katie ;

Machin, Ian ;

McDermott, Michael P. ;

McMahon, Stephen B. ;

Price, Theodore J. ;

Ross, Sarah E. ;

Scherrer, Gregory ;

Seal, Rebecca P. ;

Sena, Emily S. ;

Silva, Elizabeth ;

Stone, Laura ;

Svensson, Camilla I. ;

Turk, Dennis C. ;

Whiteside, Garth .

PAIN, 2016, 157 (04) :901-909

[10] Voltage gated sodium channels as drug discovery targets [J].

Bagal, Sharan K. ;

Marron, Brian E. ;

Owen, Robert M. ;

Storer, R. Ian ;

Swain, Nigel A. .

CHANNELS, 2015, 9 (06) :360-366

← 1 2 3 4 5 6 7 8 9 10 →